Browsing: Cognitive/neurodegenerative disorders
Join those affected by dementia, researchers and charities on our #VoicesForDementia campaign, as we try to defeat the disease!
Some EU healthcare systems have been reported to lack the capacity to rapidly move an Alzheimer’s treatment from approval into widespread clinical use.
Researchers have determined that the blood–brain barrier could be used as a possible biomarker for Alzheimer’s disease; this could potentially result in earlier diagnosis of the disease.
In this week’s round-up, we cover the latest industry news from the US FDA and the halt of an Alzheimer’s drug following a toxic reaction.
Scientists have discovered a vicious feedback loop underlying brain degeneration in Alzheimer’s, which may explain why many drug trials have failed.
At AAIC 2018, we had the pleasure of speaking with Catherine Kaczorowski about the innovative work she is doing to accelerate drug discovery in Alzheimer’s disease.
A clinical trial to determine the effects of daily low-dose aspirin has determined that aspirin does not prolong healthy, independent living free of dementia.
A simple blood test could detect the earliest changes caused by Huntington’s disease, even before scans pick up any signs in the brain.
Whilst at AAIC 2018, we spoke with Tom Russ about life course air pollution exposure and the significance of this on neurological disorders.